一名对恢复期血浆治疗有反应的重症难治性新冠肺炎患者；病例系列
A severe refractory COVID-19 patient responding to convalescent plasma; A case series.
作者信息
Abdullah Hadi Mohammed, Hama-Ali Hersh H, Ahmed Sabah Nasraddin, Ali Kosar Muhammad, Karadakhy Kamaran Amin, Mahmood Safeen Othman, Mahmood Zana Hameed, Hamad Amin Karmand Qadir, Atta Peshnyar Muhammad, Nuradeen Bryar Ezadeen, Mohammed Shvan H, Salih Rawezh Q, Baba Hiwa O, Kakamad Fahmi H
机构信息
Shar Hospital, Sulaimani, Kurdistan, Iraq.
Shahid Dr.Hemn Hospital, Sulaimani, Kurdistan, Iraq.
出版信息
Ann Med Surg (Lond). 2020 Jun 24;56:125-127. doi: 10.1016/j.amsu.2020.06.018. eCollection 2020 Aug.
INTRODUCTION
Although some medicines are under research, currently, no specific antiviral drug has been approved to target 2019 novel coronavirus. In this report two severe cases of 2019 novel coronavirus disease (COVID-19) patients have been described who received convalescent plasma (CP).
CASE REPORT
Two male cases (a 46-year-old and a 56-year-old) after being diagnosed with severe COVID-19, they deteriorated despite supportive care and antiviral therapy. They started to improve with CP infusion both clinically and radiologically. Finally they were discharged in a very well condition with negative virology tests.
CONCLUSION
CP might be an effective therapy for severe COVID-19 patients.
引言
尽管一些药物正在研究中，但目前尚无针对2019新型冠状病毒的特效抗病毒药物获批。在本报告中，描述了两例接受康复期血浆（CP）治疗的2019新型冠状病毒病（COVID-19）重症患者。
病例报告
两名男性患者（一名46岁，一名56岁）被诊断为重症COVID-19后，尽管接受了支持治疗和抗病毒治疗，病情仍恶化。接受CP输注后，他们在临床和影像学上均开始好转。最终，他们康复出院，病毒学检测呈阴性。
结论
CP可能是治疗重症COVID-19患者的有效疗法。
Zotero 插件